Broncus Holding Corp. ( (HK:2216) ) has shared an announcement.
Broncus Holding Corporation announced that its BroncAblate® Disposable Lung Radiofrequency Ablation Catheter has been approved for marketing in China by the National Medical Products Administration. This device, a world-first in natural orifice transluminal radiofrequency ablation for lung cancer, represents a significant advancement in ultra-minimally invasive interventional therapy, potentially transforming lung cancer treatment by offering a more effective and less invasive option compared to traditional methods.
More about Broncus Holding Corp.
Broncus Holding Corporation is a medical device company incorporated in the Cayman Islands, focusing on innovative solutions for lung cancer treatment. The company specializes in developing minimally invasive interventional devices, with a market focus on addressing the challenges of lung cancer treatment.
YTD Price Performance: 79.66%
Average Trading Volume: 2,900,950
Technical Sentiment Signal: Sell
Current Market Cap: HK$558.8M
Learn more about 2216 stock on TipRanks’ Stock Analysis page.